DrugPatentWatch Database Preview
ELLA Drug Profile
When do Ella patents expire, and what generic alternatives are available?
Ella is a drug marketed by Lab Hra Pharma and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-five patent family members in twenty-eight countries.
The generic ingredient in ELLA is ulipristal acetate. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ulipristal acetate profile page.
Summary for ELLA
| International Patents: | 65 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 59 |
| Patent Applications: | 51 |
| Drug Prices: | Drug price information for ELLA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ELLA |
| DailyMed Link: | ELLA at DailyMed |
Pharmacology for ELLA
| Drug Class | Progesterone Agonist/Antagonist |
| Mechanism of Action | Selective Progesterone Receptor Modulators |
Synonyms for ELLA
| (10S,11S,14R,15S,17R)-14-acetyl-17-[4-(dimethylamino)phenyl]-15-methyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-14-yl acetate |
| (11alpha,13alpha,17beta)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-yl acetate |
| (11b)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione |
| (11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-yl acetate |
| (11beta)-17-(Acetyloxy)-11-(4-(dimethylamino)phenyl)-19-norpregna-4,9-diene-3,20-dione |
| (11beta)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione |
| (8S,11R,13S,14S,17R)-17-acetyl-11-(4-(dimethylamino)phenyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate |
| [(8S,11R,13S,14S,17R)-17-acetyl-11-(4-dimethylaminophenyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate |
| [(8s,11r,13s,14s,17r)-17-Acetyl-11-[4-(Dimethylamino)phenyl]-13-Methyl-3-Oxo-1,2,6,7,8,11,12,14,15,16-Decahydrocyclopenta[a]phenanthren-17-Yl] Acetate |
| 126784-99-4 |
| 17-Acetoxy-11-(4-N,N-dimethylaminophenyl)pregna-4,9-diene-3,20-dione |
| 17beta-acetyl-11beta-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17alpha-yl acetate |
| 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-, (11beta)- |
| 19-Norpregna-4,9-diene-3,20-dione,17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11b)- |
| 4oar |
| 5-(Hydroxymethyl)-alpha,alpha,alpha,alpha-tetramethyl-1,3-benzenediacetonitrile |
| 784A994 |
| AB01566874_01 |
| AC1L2Y8A |
| AKOS026750526 |
| AMX10180 |
| BDBM50375424 |
| BRD-K64381438-001-03-8 |
| C30H37NO4 |
| CBD 2914 |
| CBD 2914; VA 2914; (11b)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione |
| CDB 2914 |
| CDB-2914 |
| CHEBI:71025 |
| CHEMBL260538 |
| CS-1157 |
| D09687 |
| DTXSID30155294 |
| EllaOne |
| EllaOne|||Esmya |
| EN300-220766 |
| FT-0675731 |
| GTPL7460 |
| Hrp-2000 |
| HY-16508 |
| J-005436 |
| KB-81383 |
| KS-00000Z24 |
| MolPort-006-170-077 |
| NCGC00378913-02 |
| OOLLAFOLCSJHRE-ZHAKMVSLSA-N |
| RTI 3021-012 |
| SC-44720 |
| SCHEMBL544957 |
| U0102 |
| Ulipristal (acetate) |
| Ulipristal acet |
| Ulipristal acetate |
| Ulipristal acetate (JAN/USAN) |
| Ulipristal acetate [USAN] |
| Ulipristal acetate, >=98% (HPLC) |
| Ulipristal acetate(CDB2914) |
| Ulipristal-Acetate |
| UNII-YF7V70N02B |
| VA2914 |
| W-5201 |
| X4788 |
| YF7V70N02B |
| Z2216208644 |
| ZINC3920657 |
US Patents and Regulatory Information for ELLA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ELLA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | Start Trial |
International Patents for ELLA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2745084 | Start Trial |
| New Zealand | 595790 | Start Trial |
| Portugal | 2419108 | Start Trial |
| Cyprus | 1118236 | Start Trial |
| Ukraine | 101863 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2010066749 | Start Trial |
| South Africa | 201104137 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
